Cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) and PD-1 blockade have proven successful in improving survival rates, resulting in the approval of the ipilimumab and nivolumab combination for the treatment of metastatic melanoma and renal cell carcinoma [23]. This evidence concerns the gene CTLA4 and renal cell carcinoma.